Biogen (BIIB) · Stock analysis

What Happened to $10,000 Invested in Biogen Stock?

By Quotelinks ·

Lab, research, chemistry
Image from Pixabay

Putting $10,000 into Biogen Inc. produced sharply different outcomes depending entirely on the time horizon. An investor who bought shares one year ago on November 19, 2025, watched that stake grow to $14,716 by November 19, 2026. That generated a 47.2% total return, which beat the S&P 500, as tracked by SPY, by 38.0 percentage points. The stock closed at $247.13, aided by a year-to-date climb of 40.4% that far exceeded the 5.8% gain for the index.

Longer horizons tell a much harsher story for shareholders. A $10,000 purchase made five years ago is now worth $9,609, representing an overall loss of 3.9%. Stretching back ten years to November 18, 2016, that initial $10,000 dwindled to $8,464, delivering a negative return of 15.4%. Over that same decade, a matching commitment to the S&P 500 grew to $38,364, creating a wide dollar shortfall of $29,901.

What would $10,000 have become over 1, 3, 5 and 10 years against the S&P 500?

Over a 1-year period, $10,000 allocated to Biogen shares expanded to $14,716, easily outpacing the broader equity market. The stock posted a total return of 47.2% since November 19, 2025, whereas the S&P 500 generated a 9.2% advance to finish at $10,920. That created an advantage of $3,796 in dollar terms and put the company ahead by 38.0 percentage points. Biogen also surpassed its industry peers, as the median S&P 500 healthcare stock gained 23.3% during the same 12-month span.

Over a 3-year holding period starting on November 17, 2023, the outcome turned decidedly weaker. A $10,000 position in Biogen ended at $10,839, which equals a total return of 8.4%, or 2.7% per year. In contrast, the S&P 500 advanced 64.7% over those three years to lift an identical stake to $16,466, delivering 18.1% per year. Biogen trailed the index by 56.3 percentage points, leaving a gap of $5,627. It also lagged its broader peer group, where the median S&P 500 healthcare stock rose 36.1%.

Across a 5-year timeframe beginning November 19, 2021, an investment in Biogen lost money. A $10,000 holding shrank to $9,609, posting a negative total return of 3.9%, which works out to a loss of 0.8% per year. Meanwhile, the S&P 500 delivered a gain of 63.2% across the same stretch, or 10.3% per year, driving a $10,000 investment up to $16,324. That left Biogen shareholders trailing the benchmark by 67.1 percentage points and facing a dollar gap of $6,715.

Extending the holding period to a full decade from November 18, 2016, highlights a dramatic performance difference. Biogen turned a $10,000 outlay into $8,464, which represents a negative total return of 15.4% and an annualized loss of 1.7% per year. By comparison, the S&P 500 soared 283.6%, compound at 14.4% per year, and turned $10,000 into $38,364. The stock trailed the broader index by 299.0 percentage points over the decade, resulting in a deficit of $29,901.

How did each of the last five calendar years go?

Biogen experienced wide performance swings across the last five calendar years, beating the market in only one of them. In 2021, the shares posted a negative return of 2.0%, while the S&P 500 rallied 28.7%. That left the company trailing the broader market by 30.7 percentage points. It was an uneven start to a volatile multi-year stretch for long-term investors.

The stock staged its sole market-beating performance of the five-year stretch during 2022. Biogen shares advanced 15.4% while the S&P 500 fell 18.2%. By gaining ground during a broad market retreat, the company outperformed the benchmark index by 33.6 percentage points. It stood out as a rare positive year for the drug maker before sharp downward pressure resumed.

Calendar year 2023 marked another reversal in relative performance for Biogen holders. The stock slipped 6.6%, while the S&P 500 recorded a substantial rebound of 26.2%. That performance gap left the company 32.7 percentage points behind the index for the year. The weakness signaled growing difficulty in keeping pace with the broader equity market's recovery.

A severe decline arrived in 2024, representing the worst calendar year of the entire five-year window. Biogen shares dropped 40.9% even as the S&P 500 gained 24.9%. The resulting performance deficit reached 65.8 percentage points. In 2025, the stock recovered with a 15.1% advance, though it still fell short of the S&P 500's 17.7% return by 2.6 percentage points.

How deep were the falls along the way, and what does the business look like today?

Steep drawdowns characterized the path for long-term shareholders across all multi-year holding periods. For the 10-year investor, the worst fall along the way reached a severe depth of 72.7%, bottoming out on April 10, 2025. The 5-year investment experienced a peak-to-trough collapse of 64.4%, hitting its low on that identical date. Even over three years, shares endured a drop of 57.6% before reaching that April 10, 2025 bottom, whereas the past year saw a much milder drawdown of 14.3% that reached its low on April 6, 2026.

At present, the company carries a market capitalization of $37.20 billion and trades on the NASDAQ exchange. The drug maker generated trailing twelve-month revenue of $10.30 billion and net income of $348.0 million. While three-year annualized revenue growth sits at a negative 1.2% per year, the latest quarterly revenue expanded by 10.6% year-over-year. The organization supports these commercial operations with a workforce of 7,500 employees.

Biogen maintains an operating margin of 24.1% and a gross margin of 70.0% over the trailing twelve months. Its bottom-line net margin stands at 3.4%, alongside a return on invested capital of 9.4%. On the balance sheet, the business carries a debt-to-equity ratio of 0.41, showing moderate leverage relative to equity. In terms of cash generation, the company produces a free cash flow yield of 6.3%.

Current trading metrics show the stock at $247.13, positioned near its 52-week high of $254.87 and well above its 52-week low of $164.42. That pricing translates to a trailing price-to-earnings ratio of 108.8x and a forward price-to-earnings ratio of 15.4x, alongside a price-to-sales ratio of 3.6x. The shares display a beta of 0.08, indicating minimal correlation with broad market volatility.

Looking ahead, investors will monitor whether Biogen can sustain its recent momentum toward the average Wall Street target. A group of 36 analysts tracks the stock, holding a mean price target of $263.60, which implies an upside of 6.7% from the last close of $247.13. For bullish expectations to materialize, quarterly revenue expansion will need to build on its recent 10.6% pace and support the transition toward that 15.4x forward valuation. Conversely, if profitability compresses back toward the recent 3.4% net margin or top-line contraction re-emerges toward the 3-year trend of negative 1.2% per year, shares could struggle to maintain their recent recovery.

Figures as of November 19, 2026. For information only, not investment advice.